WeVote
Log In

Bill

Bill

H 3092

Chemically Induced Abortions

2025-2026 Regular Session Introduced by Mike Burns and 9 co-sponsors

The bill requires providers giving mifepristone to give a mandated disclosure that the first pill may not end the pregnancy and options to continue may exist.

Member(s) request name added as sponsor: McCravy, Hiott
0
WeVote Research Nonpartisan
Bill Summary · H 3092

Summary — H 3092 (titled “Chemically Induced Abortions” / Section 44‑41‑95)

Note on source material: the provided packet appears to combine text from two different bills (a Massachusetts bill about Community Preservation Act recording fees and a South Carolina bill that would add Section 44‑41‑95 regarding chemically induced abortions). This summary focuses on the South Carolina-style text titled “Chemically Induced Abortions” (Section 44‑41‑95), since that matches the bill title. Verify the official legislative docket for final, authoritative text.

Purpose

To require that when mifepristone is administered, dispensed, or otherwise provided to a pregnant woman, the provider must give the patient a mandated disclosure statement explaining that the first pill (mifepristone) may not always end the pregnancy and that options and medications may exist to attempt to continue the pregnancy.

Key provisions

  • Provider duty: A physician (or person acting under a physician’s direction) who provides mifepristone must provide the disclosure statement to the pregnant woman at the time of provisioning.
  • Permitted methods of delivery: the disclosure may be:
    1. stapled to the package (bag/envelope) containing misoprostol for at‑home use;
    2. attached to a written prescription for misoprostol; or
    3. attached to discharge instructions if the misoprostol prescription is sent to a pharmacy.
  • Required disclosure text (exact language must be included): "PLEASE READ BEFORE TAKING SECOND PILL

Research has indicated that the first pill provided, identified as mifepristone, is not always effective in ending a pregnancy. If after taking the first pill you regret your decision, please consult a physician or healthcare provider immediately to determine if there are options available to assist you in continuing your pregnancy. Medication is also available by prescription to help restore progesterone and potentially strengthen the pregnancy if you and your physician make that decision."
- Exceptions and limits:
- The statute expressly states it does not create or recognize a right to abortion.
- The disclosure is not required for a woman experiencing a spontaneous miscarriage.
- Pharmacies or entities other than the facility where the abortion is administered are not required to provide the statement.
- Definitions included in the bill:
- “Abortion pill” = use of mifepristone or misoprostol to induce chemical abortion.
- “Mifepristone” and “misoprostol” defined by pharmacologic description.
- “Spontaneous miscarriage” defined as a natural/accidental termination (e.g., genetic or physical causes).
- Severability clause: if any part is held invalid, remaining provisions stay effective.
- Effective date: upon approval by the Governor.

Who is affected

  • Primary: physicians and clinical staff (or persons acting under physician direction) who administer, dispense, or provide mifepristone.
  • Secondary: pregnant patients receiving mifepristone; facilities that perform or supervise medication abortion care.
  • Pharmacies: explicitly not required by the bill to provide the disclosure (though prescriptions filled at pharmacies may receive discharge instructions from the originating facility).

Procedural / timeline notes (from provided metadata)

  • Prefiled: 2024‑12‑05
  • Introduced/read first time: 2025‑01‑14; referred to Committee on Judiciary (and other committee references appear in the packet)
  • Sponsor additions and committee actions recorded across 2025 (multiple sponsor additions listed and a hearing scheduled for 2025‑09‑15). Committee reported favorably and referred to House Ways and Means on 2025‑11‑19.
  • Final enactment would take effect upon the Governor’s signature.

Observations / recommended checks

  • Confirm state and bill number: the packet mixes Massachusetts and South Carolina materials. Confirm the correct jurisdiction and official bill text on the relevant state legislature website before citing or relying on this summary.
  • The bill prescribes a specific written disclosure; compliance will require clinics to integrate the statement into dispensing workflows.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.